account_balance
Investment manager · 13F filer · SEC CIK 1577524
Sarissa Capital Management LP
Reported value$178Mas of Jun 30, 2026
Positions10 1 new, 0 sold out
Top 10 weight100.0%INVA alone is 24%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
This fund reports 10 stocks.
INVAInnoviva Inc
24.1%Trimmed −11%
IRWDIronwood Pharmaceuticals Inc
21.7%
AMRNAmarin Corp PLC
15.0%
NBIXNeurocrine Biosciences Inc
11.0%
CYTKCytokinetics Inc
10.9%
LNTHLantheus Hldgs Inc
10.4%
BHVNBiohaven Ltd
4.9%Added +3%
REGN1.5%INVAInnoviva Inc
24.1%Trimmed −11%
IRWDIronwood Pharmaceuticals Inc
21.7%
AMRNAmarin Corp PLC
15.0%
NBIXNeurocrine Biosciences Inc
11.0%
CYTKCytokinetics Inc
10.9%
LNTH10.4%BHVN4.9%REGNBox size is the share of the fund. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 10 as a list
INVA Innoviva Inc 24.1% Trimmed −11%IRWD Ironwood Pharmaceuticals Inc 21.7% HeldAMRN Amarin Corp PLC 15.0% HeldNBIX Neurocrine Biosciences Inc 11.0% HeldCYTK Cytokinetics Inc 10.9% HeldLNTH Lantheus Hldgs Inc 10.4% HeldBHVN Biohaven Ltd 4.9% Added +3%REGN Regeneron Pharmaceuticals 1.5% HeldVOR Vor Biopharma Inc 0.3% HeldBIIB Biogen Inc 0.1% New
What changed